Verrica Pharmaceuticals Inc (VRCA)
0.7043
-0.04
(-5.63%)
USD |
NASDAQ |
Nov 07, 16:00
0.72
+0.02
(+2.23%)
Pre-Market: 08:49
Verrica Pharmaceuticals Revenue (TTM): 9.21M for Sept. 30, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| September 30, 2024 | 9.21M |
| June 30, 2024 | 13.91M |
| March 31, 2024 | 8.913M |
| December 31, 2023 | 5.124M |
| Date | Value |
|---|---|
| September 30, 2023 | 3.204M |
| June 30, 2023 | 8.606M |
| March 31, 2023 | 8.638M |
| December 31, 2022 | 9.032M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
3.204M
Minimum
Sep 2023
13.91M
Maximum
Jun 2024
8.329M
Average
8.776M
Median
Revenue (TTM) Benchmarks
| Biomarin Pharmaceutical Inc | 2.753B |
| Elite Pharmaceuticals Inc | 66.45M |
| Eagle Pharmaceuticals Inc | 257.55M |
| TELA Bio Inc | 64.74M |
| Terns Pharmaceuticals Inc | -- |